| Grant ID | RP190022 |
| Awarded On | February 21, 2019 |
| Title | A Randomized, Controlled Trial Comparing the Immunogenicity of 2 Doses Versus 3 Doses of the 9-Valent HPV Vaccine in Males and Females 15 to 26 Years of Age |
| Program | Academic Research |
| Award Mechanism | Individual Investigator Research Awards for Prevention and Early Detection |
| Institution/Organization | The University of Texas Medical Branch at Galveston |
| Principal Investigator/Program Director | Abbey Berenson |
| Cancer Sites | Cervix Uteri, Head and Neck, Penis |
| Contracted Amount | $1,491,473 |
| Lay Summary |
The HPV vaccine is recommended for all adolescents and young adults to prevent several types of cancer. If the vaccine series is started by 14 years of age, only 2 doses are recommended. However, if the vaccine series is started at age 15 or greater, 3 doses are recommended. It is possible that 2 doses are actually sufficient in older teens and young adults, but no one has tested this hypothesis to see if it is true. We will conduct a clinical trial to examine the immune response of older teens and young adults who receive 3 doses of the HPV vaccine as compared to the immune response of those who receive only 2 doses. We hypothesize that the immune responses will be similar, demonstrating th... |